Profile
| Metric | Value |
|---|---|
| Full Name | AnaptysBio, Inc. |
| Ticker | NASDAQ: ANAB |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | anaptysbio.com |
| Employees | 136 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $49.03 | |
| Price, 1D Change | +9.76% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.50 | |
| Revenue | $91M | |
| Revenue, 1Y Change | +432.03% | |
| EPS | -$5.12 | |
| EPS, 1Y Change | +15.80% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$5.12 | |
| EPS Estimate | -$1.40 | |
| EPS Est. Change | +72.56% | |
| Revenue | $91.28M | |
| Revenue Estimate | $205.31M | |
| Revenue Est. Change | +124.93% | |
| Current Price | $49.03 | |
| Price Target | - | $60.00 |
| Price Tgt. Change | - | +22.37% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$6.08 | -$6.08 | +0.05% | |
| -$6.18 | -$5.12 | +17.21% | |
| -$1.40 | N/A | +72.56% | |
| -$4.10 | N/A | +19.97% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $10.22M | $17.16M | +67.88% | |
| $55.93M | $91.28M | +63.22% | |
| $205.31M | N/A | +124.93% | |
| $120.73M | N/A | +32.26% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +245.04% | |
| Price, 3Y | +112.53% | |
| Market Cap, 1Y | +213.51% | |
| Market Cap, 3Y | +106.38% | |
| Revenue, 1Y | +432.03% | |
| Revenue, 3Y | +44.49% | |
| EPS, 1Y | +15.80% | |
| EPS, 3Y | -142.86% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $49.03 | |
| SMA 200 | $28.16 | |
| SMA 200 vs Price | -42.56% | |
| SMA 50 | $42.24 | |
| SMA 50 vs Price | -13.85% | |
| Beta | 0.50 | |
| ATR | $2.76 | |
| 14-Day RSI | 60.65 | |
| 10-Day Volatility | 78.30% | |
| 1-Year Volatility | 78.17% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $91.28M | |
| EPS | -$5.12 | |
| Gross Profit | $88.88M | |
| Gross Margin | 97.37% | |
| Operating Profit | -$114.95M | |
| Operating Margin | -125.93% | |
| Net Income | -$145.23M | |
| Net Margin | -159.11% | |
| EBITDA | -$92.74M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| 9.51 | ||
| 9.51 | ||
| -1.90 | ||
| 4 | ||
| 0.27 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 8.01 | ||
| -46.15 | ||
| -55.42 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $70.87M | |
| $123.08M | ||
| $483.83M | ||
| $431.88M | ||
| $412.97M | ||
| $45.43M | ||
| Total Debt | $369.46M | |
| $1.93M | ||
| $4.00M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $206.23M | ||
| $206.23M | ||
| $2.40M | ||
| $42.39M | ||
| $2.40M | ||
| $50.09M | ||
| $3,000.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$135.34M | ||
| $95.40M | ||
| $127.05M | ||
| Capex | $358.00K | |
| -$135.70M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Barclays | → | |
| Stifel | → | |
| Wedbush | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Barclays | → | |
| Truist Securities | → | |
| Wells Fargo | → | |
| Guggenheim | → | |
| Stifel | → |
Analyst sentiment
Institutional ownership
Screeners with ANAB
Data Sources & References
- ANAB Official Website www.anaptysbio.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1370053/000137005325000089/0001370053-25-000089-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1370053/000137005325000024/0001370053-25-000024-index.htm
- ANAB Profile on Yahoo Finance finance.yahoo.com/quote/ANAB
- ANAB Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/anab
FAQ
What is the ticker symbol for AnaptysBio, Inc.?
The ticker symbol for AnaptysBio, Inc. is NASDAQ:ANAB
Does AnaptysBio, Inc. pay dividends?
No, AnaptysBio, Inc. does not pay dividends
What sector is AnaptysBio, Inc. in?
AnaptysBio, Inc. is in the Healthcare sector
What industry is AnaptysBio, Inc. in?
AnaptysBio, Inc. is in the Biotechnology industry
What country is AnaptysBio, Inc. based in?
AnaptysBio, Inc. is headquartered in United States
When did AnaptysBio, Inc. go public?
AnaptysBio, Inc. initial public offering (IPO) was on January 26, 2017
Is AnaptysBio, Inc. in the S&P 500?
No, AnaptysBio, Inc. is not included in the S&P 500 index
Is AnaptysBio, Inc. in the NASDAQ 100?
No, AnaptysBio, Inc. is not included in the NASDAQ 100 index
Is AnaptysBio, Inc. in the Dow Jones?
No, AnaptysBio, Inc. is not included in the Dow Jones index
When was AnaptysBio, Inc. last earnings report?
AnaptysBio, Inc.'s most recent earnings report was on November 4, 2025
When does AnaptysBio, Inc. report earnings?
The next expected earnings date for AnaptysBio, Inc. is February 26, 2026
